文献速递头颈部肿瘤放疗放疗物理与技术

MedNext-Insight模型在鼻咽癌CT自动勾画代谢肿瘤体积及预后价值

MedNext-Insight Model for Automated Metabolic Tumor Volume Delineation on Computed Tomography and Prognostic Value in Nasopharyngeal Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-05-16

该回顾性研究纳入392例鼻咽癌患者,开发7层MedNext-Insight深度学习模型,仅用平扫CT自动勾画代谢肿瘤体积(MTV),并与nnUNetV2、Pix2Pix和3D-CycleGAN比较。

要点

  • MedNext-Insight仅用CT勾画MTV的Dice达0.808±0.110,优于nnUNetV2等对照方法。
  • 联合临床变量后C-index达0.809(95%CI 0.678–0.919),优于原发肿瘤体积特征。

核心结论

  • MedNext-Insight可在常规CT上无需PET实现准确的MTV勾画,并具有预后价值,支持资源节约型风险分层及未来生物学引导自适应放疗。

研究设计与样本

  • 回顾性队列纳入2021年接受放疗前PET/CT的392例鼻咽癌患者,随机分为训练集314例(含63例验证)和测试集78例。
  • 真实MTV由PET配准CT上原发肿瘤大体体积内SUV>2.5生成,训练7层MedNext-Insight模型以双窗CT输入和Dice-Focal损失预测MTV。
  • 与nnUNetV2、Pix2Pix和3D-CycleGAN比较,主要指标为Dice相似系数和敏感度。
  • 从预测MTV和真实MTV提取影像组学特征构建Cox模型评估无事件生存,并用2022年不同扫描仪内部队列(n=135)以计划CT为唯一输入验证稳健性。

主要发现

  • 基于MTV的影像组学优于原发肿瘤大体体积特征,联合临床变量时C-index达0.809(95%CI 0.678–0.919)。

关键数值与推荐

  • 真实MTV定义:PET配准CT上原发肿瘤大体体积内SUV>2.5。
  • 联合临床变量后C-index为0.809(95%CI 0.678–0.919)。

临床怎么用

  • 在缺乏PET的机构,可用MedNext-Insight从常规CT自动勾画MTV,替代PET依赖的MTV获取。
  • 基于预测MTV的影像组学可联合临床变量进行鼻咽癌风险分层,预后效能与PET真实MTV相当。
  • 该流程有望为生物学引导的自适应放疗提供资源节约型工具。

局限性

  • 研究为单中心回顾性设计,样本量392例,需外部多中心验证。
  • 真实MTV依赖PET/CT配准和SUV>2.5阈值,预测模型在无PET条件下的绝对误差未报告。
  • 内部队列仅135例且来自同一中心不同扫描仪,泛化性仍有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSES: To develop a deep learning model for automated metabolic tumor volume (MTV) delineation on routine computed tomography (CT) without positron emission tomography (PET) and to validate its prognostic value in nasopharyngeal carcinoma (NPC). METHODS AND MATERIALS: A retrospective cohort of 392 patients with NPC undergoing pre-radiotherapy 2-deoxy-2-[fluorine-18]fluoro-D-glucose PET/CT in 2021 was enrolled and randomly divided into training (n = 314, including 63 for validation) and test (n = 78) cohorts. Ground-truth MTV (GT_MTV) was generated from PET-registered CT using standardized uptake value SUV > 2.5 within the primary gross tumor volume. A 7-layer MedNext-Insight model with dual-window CT inputs and Dice-Focal loss was trained to predict MTV using CT alone. Segmentation performance was compared with no-new-U-Net version 2 (nnUNetV2), Conditional Generative Adversarial Network for Image-to-Image Translation (Pix2Pix), and three-dimensional Cycle-Consistent Generative Adversarial Network (3D-CycleGAN) p rimarily using Dice Similarity Coefficient and sensitivity. Radiomic features were extracted from predicted MTV (Pred_MTV) and GT_MTV to construct Cox proportional hazards models for event-free survival, evaluated by concordance index (C-index). Robustness was further assessed in an internal temporal validation cohort from 2022 with different scanners (n = 135) using planning CT as the sole input. RESULTS: MedNext-Insight achieved the highest MTV delineation Dice Similarity Coefficient (Mean ± SD, 0.808 ± 0.110 vs 0.740-0.782; all P < .05) with improved sensitivity. After excluding 12 patients with baseline distant metastasis from event-free survival analysis, Pred_MTV-derived radiomics showed strong reproducibility (median intraclass correlation coefficient, 0.816) and comparable prognostic performance to GT_MTV (C-index [95% CI], 0.712 [0.516-0.899] vs 0.744 [0.601-0.884]; P = .730). MTV-based radiomics outperformed primary gross tumor volume-derived features, particularly when combined with clinical variables (C-index, 0.809 [0.678-0.919]). In the internal temporal validation cohort, CT-only Pred_MTV maintained stable segmentation accuracy and prognostic discrimination (log-rank test, P < .05). CONCLUSION: MedNext-Insight enables accurate PET-free MTV delineation on routine CT with prognostic value, supporting a resource-efficient approach for risk stratification and informing potential future biology-guided adaptive radiation therapy in NPC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hao MY, Xiong YX, Li Y, et al. MedNext-Insight Model for Automated Metabolic Tumor Volume Delineation on Computed Tomography and Prognostic Value in Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2026. PMID: 42144163. doi:10.1016/j.ijrobp.2026.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。